GLP1R and type 2 diabetes mellitus: New antidiabetic drugs, belonging to the class of glucagon-like peptide 1 receptor agonists (GLP1-RAs) or sodium–glucose cotransporter 2 inhibitors (SGLT2is), although acting through profoundly different mechanisms, appear to improve the renal outcome in patients with T2D [8–10].